A5066769011- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Advances in Oncology and Radiotherapy
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Angiogenesis and VEGF in Cancer
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Peptidase Inhibition and Analysis
- Anatomy and Medical Technology
- Cancer survivorship and care
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
Stanford University
2016-2025
Caris Life Sciences (United States)
2023-2025
Indiana University – Purdue University Indianapolis
2012-2024
Indiana University School of Medicine
2007-2024
Stanford Medicine
2013-2024
Stanford Cancer Institute
2016-2024
Cancer Institute (WIA)
2001-2024
Cancer Prevention Institute of California
2016-2024
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2005-2023
Indiana University
2004-2023
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of in absence low; however, there uncertainty about for most patients, who have midrange score.We performed prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative cancer. Of 9719 eligible patients follow-up information, 6711 (69%) had 11 to 25 were randomly assigned receive...
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 6 inhibitor, plus fulvestrant with alone in patients advanced breast cancer (ABC). Patients Methods was global, double-blind, phase III study women hormone receptor-positive human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from end ET,...
Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, prospectively conducted study in uniformly treated population provides highest level evidence supporting clinical validity and usefulness biomarker.We performed prospective trial involving women hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary...
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs primary TNBCs two adjuvant phase III trials conducted by Eastern Cooperative Oncology Group (ECOG).Full-face hematoxylin eosin–stained sections 506 tumors from ECOG E2197 E1199 were evaluated for density intraepithelial (iTILs) stromal compartments (sTILs). Patient...
Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than single agent alone. EGF104900 compared the activity of alone or combination with trastuzumab patients ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients Methods MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either...
PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS: Cohorts metastatic cancer having failed prior therapy entered phase I trial rhuMAb VEGF administered by 90-minute intravenous infusion at doses from 0.1 10.0 mg/kg on days 0, 28, 35, 42. Patients underwent pharmacokinetic sampling day 0 had serum samples obtained during subsequent 28 days....
We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in adjuvant treatment breast cancer.
Purpose Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported 2005. One of these reports, the joint North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab Treating Women HER2-Overexpressing Breast Cancer) and National Surgical Adjuvant Bowel Project NSABP B-31 (Doxorubicin Cyclophosphamide...
OBJECTIVE: To determine indications for the use of postmastectomy radiotherapy (PMRT) patients with invasive breast cancer involved axil-lary lymph nodes or locally advanced disease who receive systemic therapy. These guidelines are intended in care outside clinical trials. POTENTIAL INTERVENTION: The benefits and risks PMRT such patients, as well subgroups these were considered. details technique also evaluated. OUTCOMES: outcomes considered included freedom from local-regional recurrence,...
Breast cancers often progress from a hormone-dependent, nonmetastatic, antiestrogen-sensitive phenotype to hormone-independent, antiestrogen- and chemotherapy-resistant with highly invasive metastatic growth properties. This progression is usually accompanied by altered function of the estrogen receptor (ER) or outgrowth ER-negative cancer cells. To understand molecular mechanisms responsible for breast cancers, activities transcription factor NF-kappaB (which modulates expression genes...
Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) patients regardless menopausal status after prior endocrine therapy (ET) has not yet been demonstrated.To compare the effect abemaciclib plus vs placebo on OS at prespecified interim MONARCH 2 (338 events) HR-positive, ERBB2-negative that progressed during ET.MONARCH was a global,...
Purpose: Between February 1993 and September 1995, 739 patients with metastatic breast cancer were entered on an Intergroup trial (E1193) comparing doxorubicin (60 mg/m 2 ), paclitaxel (175 /24 h), the combination of (AT, 50 150 h, plus granulocyte colony-stimulating factor 5 mg/kg) as first-line therapy. Patients receiving single-agent or crossed over to other agent at time progression. Methods: well balanced for on-study characteristics. Results: Responses (complete response partial...
No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has associated altered risk breast cancer and variable promoter activity. Therefore, we evaluated association VEGF genotype efficacy toxicity in E2100, a phase III study comparing paclitaxel versus plus bevacizumab as initial chemotherapy metastatic
Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall (OS) analysis from is reported here.Patients HER2-positive MBC whose disease progressed during prior trastuzumab-based therapies were...
To assess cardiac safety and potential risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial.
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on 21-gene assay to determine the risk recurrence. Whether level clinical recurrence adds prognostic information is not known.
Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site initial recurrence is an important determinant predicting survival from time recurrence. However, both estrogen receptor (ER) status axillary lymph node at diagnosis, as well length disease-free interval, provide additional independent information patient after disease Involved nodes diagnosis and/or lack ERs may indicate a highly malignant tumor or weak...